Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung

Non Small Cell Lung Cancer Clinical Trial

Official title:

Precision Radiation for OligoMetastatIc and MetaStatic DiseasE (PROMISE)-004: Consolidative Use of Radiotherapy to Block (CURB) Oligoprogression

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03808662
• Other study ID #: 18-431
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: January 16, 2019
• Est. completion date: January 2025

Study information

• Verified date: June 2024
• Source: Memorial Sloan Kettering Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is determine if receiving stereotactic body radiation(SBRT) when participants' metastatic tumors have just begun to grow increase the length of time before disease gets worse

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 107
• Est. completion date: January 2025
• Est. primary completion date: January 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age 18 or older

• Willing and able to provide informed consent

• Metastatic disease detected on imaging and histologically confirmed:

Triple negative breast cancer TNBC (ER <1%, PR <1%, her-2-neu 0- 1+ by IHC or FISH-negative or as determined by MD discretion)

OR NSCLC (without known EGFR mutation or ALK/ROS1 rearrangement)

OR Other high-risk breast cancer (per physician's discretion) progressed on hormone or systemic therapy, regardless of ER/HER2 status

OR NSCLC with EGFR, ALK, or ROS1 targetable molecular alterations with disease progression on first-line tyrosine kinase inhibitor

Note:

• Biopsy of metastasis prior to enrollment is per treating physician's discretion per standard of care. It is preferred but not required.

• These patients are selected for the study given the similar survival outcomes when given standard of care therapies

• Patient has received at least first-line prior treatment with systemic therapy (either cytotoxic or targeted, including maintenance therapies).

• Patients who received prior immunotherapy are allowed.

• Patients who had any prior radiation therapy near or overlapping with the oligoprogressive sites are allowed to enroll.

• Patients with the following medical conditions precluding them from participating in other systemic therapy or drug trials are allowed:

• active liver disease, including viral or other hepatitis, or cirrhosis

• any other significant medical condition not under control, including any acute coronary syndrome within the past 6 months.

• a permanent pacemaker

• a QTc > 480 ms in the baseline EKG

• peripheral neuropathy of grade >/= 2 per NCI CTCAE

• history or known autoimmune disease

• current chronic systemic steroid therapy or any immunosuppressive therapy

• history of primary immunodeficiency or solid organ transplant

• known positive human immunodeficiency virus (HIV), chronic or active hepatitis B or C, or active hepatitis A

• active infection requiring systemic antibiotic therapy

• Patients can have more than 5 metastases but can only have 1-5 oligo-progressive lesions.

• Oligoprogression, defined as Response Evaluation Criteria in Solid Tumors (RECIST) or Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST) documented progression in up to 5 individual lesions

Using Response Evaluation Criteria in Solid Tumors (RECIST) Criteria as a guide:

1. At least a 20% increase in the sum of the longest diameter (LD) of the lesion, taking as reference the smallest sum LD recorded since the last imaging OR

2. The appearance of one or more new lesions OR

3. New/malignant FDG uptake in the absence of other indications of progressive disease or an anatomically stable lesion OR

4. >/= 5mm increase in the diameter sum of the lesion

OR

Using Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST) as a guide:

1. >30% increase in 18F-FDG SUV peak, with >0.8 SUV units increase in tumor SUV from the baseline scan in pattern typical of tumor and not of infection/treatment effect OR

2. Visible increase in the extent of 18F-FDG tumor uptake OR

3. New 18F-FDG avid lesions typical of cancer (including new bone lesion) and not related to treatment effect and/or infection

OR

Development of a new soft tissue metastatic lesion at least 5mm in size or any new bone metastasis

OR

Progressive enlargement of a known metastasis on 2 consecutive imaging studies at least 2 months apart with a minimum 5mm increase in size

• All sites of oligoprogression can be safely treated

• Maximum 5 progressing metastases in any single extra-cranial organ system (i.e. lung, liver, bone)

a. If the clinical scenario deem that other forms of local therapy may be more suitable for the metastatic disease, such as surgical resection and interventional radiology-guided ablation, patients would be able to undergo other forms of local therapy with discussion with the PI

• No restriction on the total number of metastases

• Note: If the clinical scenario deem that other forms of local therapy may be more suitable for the metastatic disease, such as surgical resection and interventional radiology-guided ablation, patients would be able to undergo other forms of local therapy with discussion with the PI.

• For patients with brain metastases and oligoprogression elsewhere where stereotactic radiation to the brain is warranted, the brain lesions can be treated prior to randomization. This will not be counted toward the 5 progressive lesions.

• Any symptomatic metastatic sites requiring prompt palliative radiation (e.g. cord compression) can also be treated with standard of care radiation prior to randomization. This will not be counted toward the 5 progressive lesions.

1. If the clinical scenario deem that other forms of local therapy may be more suitable for the metastatic disease, such as surgical resection and interventional radiology-guided ablation, patients would be able to undergo other forms of local therapy with discussion with the PI.

Exclusion Criteria:

• Pregnancy.

• Leptomeningeal disease.

• Serious medical comorbidities precluding radiotherapy, such as ataxia-telangiectasia or scleroderma.

• Any other condition which in the judgment of the investigator would make the patient inappropriate for entry into this study.

Related Conditions & MeSH terms

• Breast Neoplasms
• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non Small Cell Lung Cancer
• Non Small Cell Lung Cancer Metastatic
• NSCLC
• NSCLC Stage IV
• NSCLC Stage IV Without EGFR/ALK Mutation
• TNBC - Triple-Negative Breast Cancer
• Triple Negative Breast Cancer
• Triple Negative Breast Neoplasms

Intervention

Radiation:
• Sterotactic Body Radiotherapy/SBRT
In general, it is recommended using 9-10 Gy x 3 or 10 Gy x 5 fractions given every other day. Physicians should try to give the highest BED whenever possible while respecting normal tissue tolerance. All lesions are recommended to receive a biologically effective dose (BED) of 60 Gy or higher (BED10=70), assuming a/ß ratio of 10 and using the linear-quadratic model: BED = nd x [1 + d/(a/ß)] where n is number of fractions and d is dose per fraction. Sometimes BED =80 Gy is preferred, with lower doses =50 Gy allowed at the discretion of the treating physician for concerns about normal tissue toxicity.

Drug:
• Standard of care
Standard of care per physician discretion

Locations

Country	Name	City	State
Canada	Princess Margaret Hospital/Ontario Cancer Institute (Data Analysis Only)	Toronto	Ontario
United States	Memorial Sloan Kettering Basking Ridge	Basking Ridge	New Jersey
United States	Memorial Sloan Kettering Commack	Commack	New York
United States	Memorial Sloan Kettering Westchester	Harrison	New York
United States	Memorial Sloan Kettering Monmouth	Middletown	New Jersey
United States	Memorial Sloan Kettering Bergen	Montvale	New Jersey
United States	Memorial Sloan Kettering Cancer Center	New York	New York
United States	Memorial Sloan Kettering Rockville Centre	Rockville Centre	New York
United States	Fred Hutchinson Cancer Research Center (Data Analysis Only)	Seattle	Washington
United States	Memorial Sloan Kettering Nassau	Uniondale	New York

Sponsors (1)

Lead Sponsor	Collaborator
Memorial Sloan Kettering Cancer Center

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression Free Survival	To study if the addition of early SBRT to extra-cranial oligo-progressive metastatic disease could prolong PFS compared to no SBRT. PFS is defined as the time from randomization to disease progression or death.	Up to 52 weeks after final participant is enrolled
Secondary	Overall survival		From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

External Links

•   Memorial Sloan Kettering Cancer Center